Citigroup Inc. Sells 186,446 Shares of Edgewise Therapeutics, Inc. $EWTX

Citigroup Inc. decreased its position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 25.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 538,453 shares of the company’s stock after selling 186,446 shares during the period. Citigroup Inc. owned about 0.51% of Edgewise Therapeutics worth $8,734,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Jones Financial Companies Lllp purchased a new position in shares of Edgewise Therapeutics in the first quarter worth about $47,000. Bessemer Group Inc. boosted its holdings in Edgewise Therapeutics by 1,170.3% in the 3rd quarter. Bessemer Group Inc. now owns 2,350 shares of the company’s stock worth $38,000 after buying an additional 2,165 shares during the period. Canada Pension Plan Investment Board purchased a new position in Edgewise Therapeutics in the 2nd quarter valued at approximately $45,000. Strs Ohio bought a new stake in Edgewise Therapeutics during the 1st quarter valued at $84,000. Finally, BNP Paribas Financial Markets raised its holdings in Edgewise Therapeutics by 48.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,193 shares of the company’s stock valued at $107,000 after acquiring an additional 2,689 shares during the period.

Analyst Ratings Changes

A number of research analysts have weighed in on EWTX shares. Stifel Nicolaus set a $25.00 target price on Edgewise Therapeutics in a report on Thursday. Piper Sandler reaffirmed an “overweight” rating on shares of Edgewise Therapeutics in a research note on Monday, February 9th. Wall Street Zen lowered shares of Edgewise Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. JPMorgan Chase & Co. raised their price target on shares of Edgewise Therapeutics from $33.00 to $34.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Finally, HC Wainwright upgraded shares of Edgewise Therapeutics to a “strong-buy” rating in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Edgewise Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $36.36.

Insider Activity at Edgewise Therapeutics

In related news, Director Badreddin Edris sold 115,471 shares of Edgewise Therapeutics stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $29.44, for a total value of $3,399,466.24. Following the transaction, the director owned 19,820 shares in the company, valued at $583,500.80. This trade represents a 85.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 23.20% of the company’s stock.

Edgewise Therapeutics News Summary

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: Multiple near‑term clinical catalysts could drive upside: management flagged CIRRUS‑HCM 12‑week data for EDG‑7500 and Phase 1 healthy‑adult data for EDG‑15400 (with planned heart‑failure studies) expected in H1 2026, and pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy anticipated in Q4 2026. These readouts materially de‑risk the pipeline and are likely the main reason investors are buying the stock. PR Newswire: Q4 & Full Year 2025 Results
• Positive Sentiment: Company increased R&D investment in Q4, signaling management is funding those near‑term trials and pivotal work — a positive for long‑term value creation if the upcoming readouts are favorable. BizWest: R&D boost
• Neutral Sentiment: Analyst modeling: HC Wainwright published quarterly EPS forecasts for 2026 (Q1 -$0.43, Q2 -$0.47, Q3 -$0.51, Q4 -$0.60; full‑year -$1.45). These estimates reinforce expectations of continued operating losses as the company advances trials; they provide a near‑term earnings framework but don’t change the pipeline narrative. MarketBeat: HC Wainwright estimates
• Neutral Sentiment: Valuation discussion: recent coverage (e.g., Yahoo Finance) examines EWTX’s strong multi‑year returns and recent momentum, useful for investors assessing whether current share price already reflects upcoming catalysts. Yahoo Finance: Valuation piece
• Negative Sentiment: Q4 earnings miss and near‑term financial drag: Edgewise reported EPS of ($0.47) for the quarter, missing the consensus ($0.43). The combination of the miss and higher R&D spend increases short‑term risk and means more funding will likely be required before positive cash flow. Press Release: Q4 Results

Edgewise Therapeutics Trading Up 2.6%

Shares of Edgewise Therapeutics stock opened at $30.44 on Monday. The business’s 50-day moving average price is $27.62 and its 200-day moving average price is $21.27. The firm has a market capitalization of $3.27 billion, a PE ratio of -18.67 and a beta of 0.26. Edgewise Therapeutics, Inc. has a 12 month low of $10.60 and a 12 month high of $31.82.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). As a group, analysts predict that Edgewise Therapeutics, Inc. will post -1.45 earnings per share for the current fiscal year.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.